Healthcare / Drug Manufacturers - Specialty & GenericJohannesburg
$34.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-89455.00 · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$152M
P/E
34.0x
↑EV/EBITDA
4949.5x
↑ROE
-127.3%
↓Gross Margin
78.2%
↑Debt/Equity
-4.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-153.2%
FCF / Net income
-2.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.7M · net income $1.2M · FCF $-2.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.7M | $1.7M | $83000.00 | — | — |
| Net Income | $1.2M | $1.2M | $21615.00 | $-91222.00 | $-62842.00 |
| EBITDA | $854278.00 | $854278.00 | $21431.00 | $-91222.00 | $-62843.00 |
| EPS | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| Gross Margin | 78.2% | 78.2% | 100.0% | — | — |
| Operating Margin | 27.9% | 27.9% | 25.8% | — | — |
| Net Margin | 71.9% | 71.9% | 26.0% | — | — |
| Balance Sheet | |||||
| Debt/Equity | -4.15 | -4.15 | -0.71 | -0.81 | -0.76 |
| Current Ratio | 3.66 | 3.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.6M | $-2.6M | $-16415.00 | $-89455.00 | — |
| Returns | |||||
| ROE | -127.3% | -127.3% | -14.7% | 21.7% | 19.1% |
| Valuation | |||||
| P/E | 34.00 | 34.00 | 50.00 | — | — |
| EV/EBITDA | 4949.51 | 4949.51 | 62.80 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 1939.2% | 1939.2% | — | — | — |
| EPS Growth | 900.0% | 900.0% | 2100.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
1046.9%
EPS terminal req.
$3.02
Spread vs growth
-146.9%
5Y implied EPS CAGR
349.0%
EPS terminal req.
$3.65
Spread vs growth
551.0%
10Y implied EPS CAGR
122.2%
EPS terminal req.
$5.88
Spread vs growth
777.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+339900.0%
Start / end P/E
50.0x → 17000.0x
EPS bridge
0.00 → 0.00
Residual
+305100.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.